Earnings Call · Q1 FY2021·2021-05-05

Q1 21EPS -33.33%·Rev n/aQ4 20EPS -39.47%·Rev n/aQ3 20EPS +11.32%·Rev n/aQ2 20EPS +33.72%·Rev n/a⚠ consensus missing

Ultragenyx Pharmaceutical Inc. RARE

Joshua Higa — Director of Investor Relations

Emil Kakkis — Chief Executive Officer

Erik Harris — Head of Commercial

Mardi Dier — Chief Financial Officer

Camille Bedrosian — Medical/Clinical Development

+9.2%1d on move date3d+3.1%5d+0.4%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more RARE calls or request research access.

More RARE calls Browse calls Request research access